AGT and cardiac hypertrophy: Interestingly, treatment with irbesartan (50 mg⋅kg–1⋅day–1), an angiotensin II type 1 receptor antagonist, prevents angiotensin II infusion-induced cardiac hypertrophy and diastolic dysfunction, which is associated with increased myocardial PDH activity and subsequent glucose oxidation rates.